-transparent.png){kind=logo}
A Phase I study of an immuno-chemotherapy regime was carried out using C. parvum as an immune-modulator. 14 women were studied. All received doses of C. parvum ranging from 2.5 mg to 21 mg administered in 1 litre of dextrose saline over 4 h. No evidence of tumour enhancement was observed.
Related Publications
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1975,
Cancer chemotherapy reports,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
September 1979,
Minnesota medicine,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
May 1979,
Cancer,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
July 1976,
Cancer,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
April 1976,
Cancer,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1976,
Annals of the New York Academy of Sciences,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1976,
Clinical bulletin,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1986,
Investigational new drugs,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1977,
Developments in biological standardization,
I H McIntosh, and
G S Thynne, and
P Bejrajati, and
G Walsh, and
W P Greening
January 1977,
Developments in biological standardization,
